These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37648226)

  • 1. Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction.
    Park SY; Kong MG; Moon I; Park HW; Choi HO; Seo HS; Cho YH; Lee NH; Lee KY; Jang HJ; Kim JS; Choi IJ; Suh J
    Korean J Intern Med; 2023 Sep; 38(5):692-703. PubMed ID: 37648226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
    Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term impact of angiotensin receptor-neprilysin inhibitor based on short-term treatment response in heart failure.
    Park HK; Park JS; Kim MS; Lee E; Choi H; Park YJ; Park BE; Kim HN; Kim N; Bae MH; Lee JH; Park HS; Cho Y; Jang SY; Yang DH
    ESC Heart Fail; 2023 Dec; 10(6):3430-3437. PubMed ID: 37705397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40.
    Zhao M; Xin Y; Li J; Cao X; Liu X
    Medicine (Baltimore); 2019 Sep; 98(39):e17296. PubMed ID: 31574852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of heart failure patients with reverse left ventricular remodelling post-angiotensin receptor blockers/neprilysin inhibitors therapy.
    Maizels L; Wasserstrum Y; Fishman B; Segev A; Ben-Nun D; Younis A; Freimark D; Mazin I; Grupper A
    ESC Heart Fail; 2022 Jun; 9(3):1682-1688. PubMed ID: 35178886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Experience of Angiotensin Receptor-Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease.
    Chang HY; Lin CC; Chao CJ; Lin YC; Wang YC; Liao CT; Huang JL; Lee YH; Huang CY; Chien LN; Hsu CY
    Mayo Clin Proc; 2023 Jan; 98(1):88-99. PubMed ID: 36109207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.
    Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC
    ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of angiotensin receptor neprilysin inhibitor therapy in heart failure patients with reduced ejection fraction: A retrospective cohort study.
    Koçak A; Aydin S; Alibaşiç H; Çiçek M; Ekici B
    Medicine (Baltimore); 2023 Oct; 102(43):e35589. PubMed ID: 37904474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of angiotensin receptor-neprilysin inhibitor on insulin resistance in patients with heart failure.
    Kashiwagi Y; Nagoshi T; Kimura H; Tanaka Y; Oi Y; Inoue Y; Ogawa K; Kawai M; Yoshimura M
    ESC Heart Fail; 2023 Jun; 10(3):1860-1870. PubMed ID: 36942494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis.
    Rattanavipanon W; Sotananusak T; Yamaae F; Chandrsawang A; Kaewkan P; Nathisuwan S; Yingchoncharoen T
    BMC Cardiovasc Disord; 2021 Jul; 21(1):324. PubMed ID: 34215190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real-world study in Taiwan.
    Chang PC; Wang CL; Hsiao FC; Wen MS; Huang CY; Chou CC; Chu PH
    ESC Heart Fail; 2020 Oct; 7(5):3003-3012. PubMed ID: 32720478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term efficacy of angiotensin receptor-neprilysin inhibitor treatment in patients with ST-segment elevation myocardial infarction with reduced ejection fraction after primary percutaneous coronary intervention: a propensity score matching study.
    Zhang Q; Qiao B; Han Y; Sun S; Wang B; Wei S
    BMC Cardiovasc Disord; 2022 Nov; 22(1):463. PubMed ID: 36333668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study.
    Wang X; Pu J; Wang G; Xu H; Liu L; Li Z; Qin R; Zhao X; Li M; Hao Z; Hu H
    BMC Cardiovasc Disord; 2023 Jul; 23(1):343. PubMed ID: 37430227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diuretic and renal effects of angiotensin receptor-neprilysin inhibitor in patients hospitalized for acute heart failure.
    Setoguchi N; Horiuchi Y; Kawakami T; Nakase M; Watanabe Y; Ishizawa T; Sekiguchi M; Nakajima M; Nonaka H; Asami M; Yahagi K; Komiyama K; Yuzawa H; Tanaka J; Aoki J; Tanabe K
    Heart Vessels; 2023 Aug; 38(8):1042-1048. PubMed ID: 36854753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR).
    Ekici B; Yaman M; Küçük M; Dereli S; Yenerçağ M; Yiğit Z; Baş MM; Karavelioğlu Y; Çakmak HA; Kıvrak T; Özkan H; Altın C; Şabanoğlu C; Demirkan B; Ataş AE; Kılıçaslan F; Altay H; Tengiz İ; Fahri Erkan A; Kılıçaslan B; Olgun FE; Durakoğlugil ME; Alhan A; Zoghi M
    Turk Kardiyol Dern Ars; 2021 Jul; 49(5):357-367. PubMed ID: 34308869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin Receptor Neprilysin Inhibitor Use and Blood Pressure Lowering in Patients With Heart Failure With Reduced Ejection Fraction Across the Spectrum of Kidney Function: An Analysis of the Veterans Administrative Health System.
    Gjyriqi G; York M; Abuazzam F; Herzog CA; Bangalore S; Lo KB; Sidhu MS; Vaduganathan M; Rangaswami J; Mathew RO
    J Card Fail; 2023 Mar; 29(3):258-268. PubMed ID: 36516938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.